To date, alpha-1 antitrypsin augmentation is the only treatment showing the ability of reducing circulating desmosine levels in a randomised trial although the magnitude of treatment effect was small26 and it is currently only relevant to alpha-1 antitrypsin deficiency, a rare genetic condition that is associated with emphysema. The gene discussed is SERPINA1; the disease is pulmonary emphysema.